This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Viral Infections  • Public Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2007;298:32.

	Since this article does not have an abstract, we have provided the first 139 words of the full text and any section headings.

Antibodies from individuals who survived an infection with avian influenza may effectively neutralize H5N1 strains, according to research from the National Institute of Allergy and Infectious Diseases, in Bethesda, Md; the Hospital for Tropical Diseases, in Ho Chi Minh City, Vietnam; and the Institute for Research in Biomedicine, in Bellinzona, Switzerland (Simmons CP et al. PLoS Med. 2007;4[5]:e178).

Anti-H5N1 human monoclonal antibodies administered to mice subsequently challenged with H5N1 caused a statistically significant reduction in pulmonary virus titer, reduced associated inflammation in the lungs, and restricted extrapulmonary dissemination of the virus. The antibodies also protected the mice from lethal doses of H5N1 when given up to 72 hours after infection.

The authors concluded that a panel of antibodies from convalescent patients might be useful for prophylaxis or adjunctive treatment of human cases of H5N1 influenza.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?